Bristol-Myers Squibb reports slight increase in second-quarter sales

Share this article:

Despite increased competition from generics, Bristol-Myers Squibb (BMS) reported a slight increase in its second-quarter sales results.

Second-quarter net sales were at $4.9 billion, up 1% over the same period a year earlier.

Sales of BMS' blood thinner Plavix, the company's top-selling drug, rebounded after a generic version made by Canadian generics company Apotex briefly entered the US market late last year.

Plavix sales were up 3.8% to $1.1 billion in the second-quarter from $1.0 billion.
 
A federal court judge recently upheld Plavix's patent exclusivity until 2011.

Plavix was the No. 2 selling drug behind Pfizer's Lipitor in 2005, with global sales of $5.9 billion.  
Second-quarter sales of schizophrenia drug Abilify were up 27% to $412 million.
 
Sales of AIDS drug Reyataz were rose 7.6% to $254 million.
 
Hypertension drugs Avapro and Avalide posted a combined 6.1% increase to $297 million.
 
Meanwhile, sales of oncology drug Erbitux dropped 5.8% to $162 from $172 million a year earlier. BMS pays royalties to ImClone Systems on Erbitux. Both companies recently announced that a late-stage study of the drug in lung-cancer patients didn't meet the primary endpoint of progression-free survival.

The company's once popular cholesterol drug Pravachol, which lost patent protection in April 2006, saw its sales shrink by 59% in the second-quarter to $132 million from $323 million in the year earlier period.  

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...